Extension of the randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.
Active, not recruitingNL-OMON49415
Acesion Pharma ApSAtrial fibrillation
supraventricular tachycardia
Start: 2020-11-04Target: 32Updated: 2025-09-08